FGF21 Receptor Agonists – Target Pipeline List 07/2019
Targets: FGF21 receptor; FGF-21 receptor; Fibroblast Growth Factor 21 receptor; FGF receptor 1 (FGFR1) coreceptor βKlotho (KLB); FGFR1/KLB
This Target Pipeline List provides an overview of FGF21 receptor agonists in development for treatment of obesity, diabetes and non-alcoholic steatohepatitis (NASH). Fibroblast growth factor 21 (FGF21) analogs and FGF21 receptor agonists (FGF21RAs) that mimic FGF21 ligand activity constitute the new “FGF21-class” of anti-obesity and anti-diabetic molecules that improve insulin sensitivity, ameliorate hepatosteatosis and promote weight loss. The therapeutic utility of this class of molecules is being actively investigated in clinical trials for the treatment of type 2 diabetes and non-alcoholic steatohepatitis (NASH). Molecules in development include modified FGF21 as well as agonistic antibodies against the receptor for FGF21, namely the complex of FGF receptor 1 (FGFR1) and the obligatory coreceptor βKlotho (KLB).
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
Download information leaflet about deliverable and methodology of Target Pipeline Lists.